Abbreviations & Acronyms BCR = biochemical recurrence BCRFS = biochemical recurrence-free survival BMI = body mass index CI = confidence interval ED = erectile dysfunction GS = Gleason score IQR = interquartile range LN = lymph node NCCN = National Comprehensive Cancer Network OR = odds ratio PCa = prostate cancer PLND = pelvic lymph node dissection PSA = prostate-specific antigen PSM = positive surgical margin RARP = robot-assisted radical prostatectomy RCT = randomized controlled trial RP = radical prostatectomy RS-RARP = Retzius-sparing robot-assisted radical prostatectomy SD = standard deviation SHIM = sexual health inventory for men Objectives: Our aim was to evaluate the predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy. Methods: The study cohort consisted of 359 consecutive non-metastatic prostate cancer patients who underwent Retzius-sparing robot-assisted radical prostatectomy between November 2012 and January 2016. According to the National Comprehensive Cancer Network prostate cancer risk classification, 164 patients (45.7%) had high-or very high-risk prostate cancer. No patient received adjuvant therapy until documented biochemical recurrence. Biochemical recurrence-free survival was estimated using the Kaplan-Meier method. Univariable and multivariable Cox proportional hazards regression models were used to determine variables predictive of biochemical recurrence. Results: The median follow-up period was 26 months (interquartile range 19-38 months). The overall biochemical recurrence rate was 14.8%, and the median time to biochemical recurrence was 11 months (interquartile range 6-22 months). The 3-year biochemical recurrence-free survival probability was 71.2%, 72.1%, 88.7%, 82.3% and 95.7% in very high-, high-, intermediate-, low-and very low-risk prostate cancer, respectively (log-rank, P < 0.001). On multivariable analysis, preoperative prostate-specific antigen (hazard ratio 1.03, 95% confidence interval 1.02-1.04; P < 0.0001), percentage of maximum core involvement on biopsy (hazard ratio 1.02, 95% confidence interval 1.01-1.03; P = 0.029) and clinical stage ≥T3a (hazard ratio 2.12, 95% confidence interval 1.02-4.39; P = 0.043) were predictors of biochemical recurrence, whereas pathological Gleason score ≥8 (hazard ratio 5.63, 95% confidence interval 1.62-19.61; P = 0.007) and pathological tumor volume (hazard ratio 1.08, 95% confidence interval 1.04-1.20; P < 0.001) were the main pathological predictors of biochemical recurrence. Conclusions: Retzius-sparing robot-assisted radical prostatectomy confers effective biochemical recurrence control at the mid-term follow-up period. Preoperative prostatespecific antigen, advanced clinical stage and higher Gleason score were important predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy. Long-term oncological safety still needs to be established.
Introduction
RP is considered an effective treatment option in the management of patients with localized PCa. 1 BCR is widely used as a primary end-point to assess treatment success, and usually prompts the initiation of secondary therapy. Approximately 35% of patients are at risk of BCR within 10 years after RP, [2] [3] [4] with a mean time from BCR to metastasis of 8 years and a mean time from metastasis to death of 5 years. 5 Since the introduction of robotic surgery in the past decade, RARP has become very popular in the USA and Europe. It has been estimated that >75% of radical prostatectomies are carried out using the da Vinci platform. 6 Recently, a meta-analysis 7 and a prospective RCT 8 showed that RARP has similar oncological outcomes to other RP approaches.
Galfano et al. described the RS-RARP, which achieved earlier recovery of continence and potency without compromising the oncological outcome. 9 At a median follow-up period of 15 months, the 1-year BCRFS probability was 89% and 92% in the first 100 patients and second 100 patients that received RS-RARP, respectively. 10 However, there is a paucity of data regarding the mid-term oncological outcomes; that is, BCR and its predictors after RS-RARP. Previous studies had a small number of patients, patients had organconfined PCa and BCR was not analyzed extensively. 9, 10 Herein, we tried to overcome these limitations by including a larger cohort of heterogeneous PCa patients with assessment of BCR at mid-term follow up.
In the present study, our aim was to evaluate the BCR and its predictors after RS-RARP, as well as to compare the BCR rate of high-risk patients with literature data of conventional robotic prostatectomy.
Methods

Patient selection and clinical variables
Data of 413 patients with clinically non-metastatic PCa (M0N0) received RS-RARP from November 2012 to January 2016 by a single high-volume robotic surgeon at the Yonsei Severance Hospital, South Korea were extracted from our prospectively maintained database with an institutional review board approval number (IBR number: 2014-0090-001). Of note, there was no certain criterion to carry out RS-RARP or any other surgical approach, as Dr Rha, the main surgeon, has carried out only RS-RARP to treat all his patients since late 2012. The following were the exclusion criteria: patients who had missed PSA records postoperatively (n = 18), received neoadjuvant or prior therapy (n = 22), had incomplete pathological data (n = 11), or had adjuvant treatments before documented BCR (n = 3). A total of 359 patients were the participants of the current study. All patients had at least six core prostate biopsies and preoperative PSA measurement. Referee pathologists reviewed all biopsies according to guidelines of the American Joint Committee on Cancer 2009.
Patients were stratified into five risk groups according to the NCCN risk classification. High-and very high-risk PCa patients were defined as (PSA >20 ng/mL, clinical stage ≥T3a and/or biopsy GS 8-10). The clinical variables recorded including age, BMI, preoperative PSA level (ng/ mL), prostate weight (gm), biopsy GS, number of biopsy positive cores, and the percentage of maximum core involvement on biopsy, PCa clinical stage, SHIM score, PLND technique and nerve-sparing status.
Pathological variables
We used the Stanford Protocol to evaluate pathological specimens. All RP specimens were analyzed by an experienced genitourinary pathologist. The pathological variables recorded including pathological T stage, pathological GS, pathological prostate weight (gm), pathological tumor volume (cc), and the presence of LN invasion, perineural invasion, angiolymphatic invasion and surgical margin status. PSM was defined as the presence of tumor cells at the inked margin of the prostatic specimen. Tumor volume was calculated as described previously in our work. 11 The pathologist used the visual estimation, as follows: the tumor area was outlined and measured in the x "the diameter of the major axis" and y "the diameter of the minor axis" of the largest area. Then, the tumor area was multiplied by its depth, according to the existence of the tumor in the subsequent sections and the thickness of each section. Finally, the total sum of all tumor foci represented the calculated tumor volume.
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Surgical technique
Surgery was carried out by using the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA). All patients were fully informed with regard to the possible complications of the surgical approach. A video showing the detailed surgical steps was included for demonstration of the RS-RARP approach (Video S1). PLND was carried out if serum PSA >10 ng/mL, there was a palpable nodule on DRE or primary biopsy GS ≥4 on biopsy. Standard PLND; that is, external iliac and obturator LNs, was carried out in patients with low-to intermediate-risk PCa, whereas extended PLND; that is, external iliac, obturator, iliac and presacral LNs, was carried out in patients with high-risk PCa. Nerve sparing was undertaken on individual surgeon discretion based on clinical stage, patient age and the patient's sexual function.
Postoperative follow up
After RARP, all patients were managed according to our standard postoperative protocol during their hospital stay. Patients were seen on postoperative days 8-10 by the surgeon for removal of the urinary catheters. A retrograde urethrocystogram was carried out as a routine imaging study before removal of the urethral catheter to ensure proper healing of the urethrovesical anastomosis. Any proved anastomotic extravasation/leak was managed by reinsertion of a new urethral catheter for an additional 1 week. After catheter removal, patients were instructed to carry out daily pelvic floor muscle training.
BCR was followed up by serial measurement of serum PSA in the same laboratory at 1-, 3-, 6-, 9-and 12-months in the first year, then twice yearly. BCR was defined as two consecutive elevations of serum PSA >0.2 ng/mL after 4 weeks of surgery.
All patients were typically followed up and asked to fill out the validated International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form at 1-, 2-, 3-, 6-and 12-months. 12 Continence was defined as wearing no pad use or use of only one protective liner per day. Patients who used two or more pads per day were considered incontinent.
Outcomes assessment
Primary end-points were to evaluate the overall BCR rate, the BCRFS probability, predictors of BCR and to compare BCR rate of high-risk patients with literature data of conventional robotic prostatectomy ( Table 4 ). The secondary end-point was to assess the urinary continence function within the first year after surgery.
Statistical analysis
For continuous data, variables are presented as mean AE SD or median and IQR. Categorical variables were specified as the frequency (percentages). Kaplan-Meier analysis and the log-rank test were used to compare time to BCR, the probability of BCR and the recovery of urinary continence during the follow-up period. Univariable and multivariable Cox proportional hazards regression analyses were carried out to determine preoperative and pathological predictors of BCR. A P-value of <0.05 was considered statistically significant. Analysis was carried out using SPSS v23 software (IBM SPSS Statistics; IBM Corporation, Armonk, NY, USA).
Results
Baseline clinical variables for the 359 patients in the present cohort are shown in Table 1 . The mean age of our cohort was 65.7 years and the median preoperative serum PSA level was 8.1 ng/mL (IQR 5.5-14.1 ng/mL). The median followup period for the entire cohort was 26 months (IQR 19-38 months). According to the NCCN PCa risk classification, 7%, 11.4%, 35.9%, 27.6% and 18.1% of patients in our cohort had very low-, low-, intermediate-, high-and very-risk PCa, respectively.
Intraoperatively, ureteric injury occurs in one patient (0.3%) and rectal injury occurs in one patient (0.3%). Regarding the early perioperative period, the median duration of catheterization was 8 days (IQR 8-9 days). Minor complications (i.e. Clavien grade 1-3a) were as follows: 3.9% mild fever, 0.8% fever requiring treatment, 4.7% ileus, 1.7% blood transfusion, 4.5% scrotal swelling and ecchymosis, 1.1% anastomotic leak, 0.3% hematuria with clot retention, 1.4% wound infection, 0.6% urinary tract infection, 2.8% abdominal wall swelling and ecchymosis, 1.1% pneumonia and pleural effusion, and 0.3% deep vein thrombosis. The overall major (i.e. Clavien grade ≥3b) complication rate was 1.4% as follows: 0.3% pulmonary embolism, 0.3% sepsis and septic Total sample n = 359.
shock, and 0.6% wound dehiscence requiring secondary suturing. Pathological variables and oncological outcomes for the 359 patients in the present cohort are shown in Table 2 . The median pathological tumor volume was 1.6 cc (IQR 0.8-3.9 cc). There was pathological GS ≥8 disease in 21.7% and ≥pT3a disease in 43.7% of the present study cohort. PSMs were present in 29 (14.6%) patients with pT2 disease, 42 (40.8%) with pT3a disease, 31 (67.4%) with pT3b disease and eight (100%) with pT4 disease. The incidence of positive LN, perineural invasion and angiolymphatic invasion was 6.1%, 63.8% and 8.9%, respectively.
The BCR rate for the entire cohort was 14.8% (53 patients) at a median follow-up period of 26 months. The overall actuarial BCRFS was 92.1%, 86.5% and 80.9% at 1, 2 and 3 years, respectively. The 3-year BCRFS probability was 71.2%, 72.1%, 88.7%, 82.3% and 95.7% in very high-, high-, intermediate-, low-and very low-risk PCa, respectively (logrank, P < 0.001; Fig. 1a ). Among the high-risk PCa patients, the median follow-up period was 30 months (IQR 20-39 months), the PSM rate was 41.2%, the BCR rate was 22% and the 3-year BCRFS rate was 72%.
The 3-year BCRFS rates when analyzed based on preoperative PSA level (>20 ng/mL), maximum biopsy core involvement ≥81% and stage ≥cT3a were 64.7%, 69.9% and 65.9%, respectively (Fig. 1b-d) ; meanwhile, when stratified by postoperative pathological parameters pathological GS ≥8 and tumor volume ≥3.9 cc pT3 were 65% and 66.3%, respectively (Fig. 2a,b) . According to pathological stage (Fig. 2c) , patients with pT2 had a higher BCRFS rate of 89.5% compared with patients with pT3a 75.2% and ≥pT3b 65.2% (log-rank, P < 0.001). Furthermore, patients with a PSM rate had a lower BCRFS rate of 76.3% compared with patients with a negative surgical margin of 84% (log-rank, P = 0.009; Fig. 2d) . Tables 2 and 3 show data of the multivariable Cox proportional hazards regression models for predictors of BCR. Among preoperative clinical variables, preoperative PSA (HR 1.03, 95% CI 1.02-1.04; P < 0.0001), percentage of maximum core involvement on biopsy (HR 1.02, 95% CI 1.01-1.03; P = 0.029) and clinical stage ≥T3a (HR 2.12, 95% CI 1.02-4.39; P = 0.043) were predictors of BCR (Table 2) . When considering postoperative pathological variables (Table 3) , pathological GS ≥8 (HR 5.63, 95% CI 1.62-19.61; P = 0.007) and pathological tumor volume (HR 1.08, 95% CI 1.04-1.20; P < 0.001) were the main pathological predictors of BCR.
Regarding postoperative functional outcomes, the urinary continence rates at 1-, 2-, 3-, 6-and 12-months were 64.9%, 79.1%, 85.5%, 91.6% and 93.9%, respectively ( Table 1 ). The recovery of urinary continence rate is shown in Figure 3 . The median SHIM score was 12.2, and just 9.7% of patients were potent (i.e. SHIM ≥22) before surgery ( Table 1) .
Discussion
There have been significant changes in the surgical management of PCa in recent years. With increased use and adoption of minimally invasive surgery, RARP has become the most widely used approach of surgical treatment for patients with localized PCa in the USA. 13 Surgeons have used different techniques to improve robotic surgery outcomes. Recently, RS-RARP has been introduced with encouraging rapid urinary continence and sexual function recovery. Furthermore, Dalela et al. in their recent prospective RCT reported that RS-RARP has earlier recovery of urinary continence compared with conventional RARP. 10 However, there is a paucity of data regarding oncological safety of RS-RARP, and its oncological outcome remains to be determined.
In the current study, we present the mid-term oncological outcomes (median 26 months) of our entire RS-RARP experience of 359 heterogeneous PCa patients. This cohort of patients had high aggressive PCa: 27.6% and 18.1% of patients had high-risk and very high-risk PCa, 21.7% had pathological GS 8-10, and 43.7% had ≥pT3 disease on final pathology. In the present analysis, the mid-term BCRFS rate was 92.1% and 80.9% at 1 and 3 years, respectively. Previously, Galfano et al. reported the BCRFS of 200 patients who underwent RS-RARP with a median follow-up period of 15 months (IQR 13-17 months). The 1-year BCRFS rate was 89% and 92% in the first 100 patients and second 100 patients, respectively. 9 The overall PSM rate in the present cohort was 30.6%, which is slightly higher than previous RS-RARP reports of 25% 9 and 26%. 10 This might be related to the higher rate of 43.7% for pT3-T4 in the present compared with the Galfano et al. study, where the PSM rate was 32% in ≥pT3 disease. 9 In addition, the present cohort had >45% high-and very high-risk PCa patients; in contrast, Dalela et al. included patients with low-and intermediate-risk PCa only. 10 However, when PSM rates were stratified according to the pathological stage, they were comparable with previous conventional RARP reports. 14, 15 In the present study, PSMs were present in 14.6%, 40.8%, 67.4% and 100% of patients with pT2, pT3a, pT3b and pT4 disease, respectively. A recent study of 5152 consecutive patients underwent conventional RARP showed PSMs in 11.2% of patients with pT2 disease and 50.5% of patients with pT3-pT4 disease.
14 Similarly, in a study by Menon et al. of 1384 consecutive patients with localized PCa who underwent conventional RARP, the overall PSM was 25.1% (13.1% in patients with pT2 and 60.5% in patient with pT3-4). 15 Regarding the BCR rate in the present study, 14.8% of patients had BCR with a median BCR time of 11 months. Among high-risk PCa patients, the BCR rate was 22%. The present results are in agreement with a large number of recent conventional RARP studies for high-risk PCa patients. The BCR rate ranged from 9.4% to 33%, as shown in Table 4 . [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Of note, the overall 3-year BCRFS was 80.9%, and when stratified by risk groups it was 72% in high-risk PCa patients. Similarly, the 3-year BCRFS rate ranged 41.4-86% at a median follow-up period of 23.6-37.3 months (Table 4) . 17, 21, 25 Despite high-risk PCa patients being defined according to the D'Amico risk classification in most of the studies (Table 4) , the present results were similar to the other studies that used NCCN criteria. 19, 23, 24 Notably, Lee et al. evaluated 250 highrisk PCa patients after conventional RARP. The PSM rate was 36%, and the 5-year BCRFS rate was 67.8%. 24 In addition, Punnen et al. studied 233 high-risk PCa patients at median follow-up period of 27 months. The 2-year and 4-year BCRFS were 79% and 66%, which were in line with our 3-year BCRFS of 72%. 23 The predictors of BCR have been extensively studied in a large number of studies in the literature. The present study showed that among preoperative clinical variables, PSA, percentage of maximum core involvement on biopsy and clinical stage ≥T3a were predictors of BCR, whereas tumor volume and pathological GS were the main pathological risk factors. The present results are in accordance with literature data. 14, 15 Preoperative PSA and pathological GS ≥8 are well-known predictors of BCR after surgery. 14, 15 Previous studies have appraised the importance of the total percentage of biopsy tissue with cancer as a predictor of advanced pathological stage and PSA recurrence, and recommended its inclusion in preoperative predictive models for prognosticating outcomes after primary treatment. 27, 28 Similarly, in a recent meta-analysis, tumor volume is significantly associated with BCR. 29 Regarding urinary continence rate at 1 year, 93.9% of the present patients were continent. Recently, Galfano et al. reported a 96% continence rate at 1 year after RS-RARP. 9 Similarly, Dalela et al. reported a 95% continence rate at 3 months after RS-RARP. 10 These results emphasize the advantages of RS-RARP for the preservation of urinary function after surgery.
From our experience with both the conventional and RS procedures, we believe that RS-RARP will have an essential role in future robotic prostatectomy surgery. Recently, a RCT with level 1 evidence showed its superiority in early urinary continence recovery compared with conventional robotic prostatectomy. 10 Although the long-term oncological outcomes are still uncertain, our mid-term oncological outcomes are encouraging. Recently, several researchers have reported their early experience with RS-RARP, and we expect widespread use of this approach soon. There were several strengths to the present study. First, to our knowledge, this study is the first to provide a stratified analysis of patients with non-metastatic PCa treated with RS-RARP. Second, almost half of the patients had high-risk PCa; as well as the BCR rate and the 3-year BCRFS rate being comparable with the majority of previous conventional RARP reports of high-risk PCa patients, which are considered additional advantages of RS-RARP in addition to its superior early recovery of continence 9, 10 and sexual function. 9 Finally, secondary treatment was not given until documented BCR, so the study gives an excellent portrayal of the natural history of non-metastatic PCa treated with RS-RARP alone.
In contrast, the present study is not devoid of limitations. First, as with all retrospective studies, a selection bias might exist. Second, it represents tertiary institution care and a single expert surgeon who carried out >1300 of conventional RARP before starting the RS approach. Thus, the results should be extrapolated carefully before generalization to lowvolume robotic centers. Third, the median follow-up period was 26 months, which might not be long enough to arrive at a meaningful conclusion regarding the long-term survival outcomes of RS-RARP; however, this approach was recently introduced in 2010 and we started it in late 2012. In addition, 25% of the cohort had 39 months of follow up. Finally, the postoperative potency rate of this surgical approach was not assessed, as the majority of the present patients had a low preoperative SHIM score before surgery. Of note, just 9.7% had normal erectile function with a SHIM score ≥22. However, an excellent potency rate was reported by Galfano et al. 9 Another reason for not reporting on the postoperative sexual function is that the follow-up SHIM questionnaires are insufficient in our database.
In a contemporary cohort of patients with a large number of high-risk PCa, RS-RARP confers effective mid-term BCR control similar to large reports of conventional robotic prostatectomy. Longer follow up is required with larger cohorts of patients to further evaluate its long-term oncological safety.
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